{"id":"https://openalex.org/W4406541557","doi":"https://doi.org/10.1158/1078-0432.28227602","title":"Supplementary Figure S8 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer","display_name":"Supplementary Figure S8 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer","publication_year":2025,"publication_date":"2025-01-17","ids":{"openalex":"https://openalex.org/W4406541557","doi":"https://doi.org/10.1158/1078-0432.28227602"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.28227602","doi":"https://doi.org/10.1158/1078-0432.28227602","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.28227602","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.28227602","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109393906","display_name":"Jesus Del Santo Anampa","orcid":"https://orcid.org/0000-0002-1898-180X","observed_orcids":["https://orcid.org/0000-0002-1898-180X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jesus D. Anampa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1898-180X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103397917","display_name":"Daniel Lee Flynn","orcid":"https://orcid.org/0000-0002-3752-7370","observed_orcids":["https://orcid.org/0000-0002-3752-7370"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel L. Flynn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3752-7370","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088727544","display_name":"Cynthia B. Leary","orcid":"https://orcid.org/0009-0009-1980-1434","observed_orcids":["https://orcid.org/0009-0009-1980-1434"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia Leary","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-1980-1434","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110977800","display_name":"Sun Young Oh","orcid":"https://orcid.org/0009-0005-3197-9180","observed_orcids":["https://orcid.org/0009-0005-3197-9180","https://orcid.org/0009-0008-8132-3771"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sun Oh","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-3197-9180","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100662163","display_name":"Xiaonan Xue","orcid":"https://orcid.org/0000-0003-2872-8119","observed_orcids":["https://orcid.org/0000-0003-2872-8119"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaonan Xue","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2872-8119","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002393604","display_name":"Maja H. Oktay","orcid":"https://orcid.org/0000-0002-8115-3898","observed_orcids":["https://orcid.org/0000-0002-8115-3898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maja H. Oktay","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8115-3898","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014100567","display_name":"John S. Condeelis","orcid":"https://orcid.org/0000-0001-8826-2336","observed_orcids":["https://orcid.org/0000-0001-8826-2336"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John S. Condeelis","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8826-2336","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5085875361","display_name":"Joseph A. Sparano","orcid":"https://orcid.org/0000-0002-9031-2010","observed_orcids":["https://orcid.org/0000-0002-9031-2010"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph A. Sparano","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9031-2010","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.33230000734329224,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.33230000734329224,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.2969000041484833,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.20569999516010284,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rebastinib","display_name":"rebastinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9710000157356262},{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":1.0},{"id":"https://openalex.org/keywords/her2-negative-metastatic-breast-cancer","display_name":"HER2-negative metastatic breast cancer","score":0.9399999976158142},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.4779999852180481},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7789999842643738},{"id":"https://openalex.org/keywords/monocyte-depletion","display_name":"monocyte depletion","score":0.3269999921321869}],"concepts":[{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.9869450330734253},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.7195038795471191},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6979668736457825},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5935993790626526},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5601469278335571},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5030211806297302},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4482342600822449},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4465394914150238},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.44075578451156616},{"id":"https://openalex.org/C2910363380","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"HER2 negative","level":5,"score":0.4166378676891327},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3821781575679779},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.18560662865638733},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.15435010194778442},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.28227602","doi":"https://doi.org/10.1158/1078-0432.28227602","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.28227602","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/28227602","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_S8_from_Phase_Ib_Clinical_and_Pharmacodynamic_Study_of_the_TIE2_Kinase_Inhibitor_Rebastinib_with_Paclitaxel_or_Eribulin_in_HER2-Negative_Metastatic_Breast_Cancer/28227602","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.28227602","doi":"https://doi.org/10.1158/1078-0432.28227602","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.28227602","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9476000070571899,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2796001254","https://openalex.org/W2416167623","https://openalex.org/W2314283413","https://openalex.org/W2613871272","https://openalex.org/W3153808353","https://openalex.org/W3160156778","https://openalex.org/W2767183100","https://openalex.org/W2613657120","https://openalex.org/W2884577979","https://openalex.org/W2587781731"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"S8":[2],"shows":[3],"the":[4],"effect":[5],"of":[6],"chemotherapy":[7,30],"or":[8],"rebastinib":[9,19,21,32],"on":[10],"TIE2":[11,16,27],"monocytes.":[12],"A,":[13],"Trends":[14],"in":[15,26],"monocytes":[17,28],"with":[18,29],"and":[20,31],"plus":[22,33],"chemotherapy;":[23],"B,":[24],"trends":[25],"chemotherapy.":[34],"Each":[35],"line":[36],"represent":[37],"data":[38],"from":[39],"one":[40],"patient":[41],"over":[42],"time.":[43],"Abbreviations:":[44],"C,":[45],"Cycle;":[46],"D,":[47],"Day.":[48]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2025-10-10T00:00:00"}